Promise and challenge of RNA interference-based therapy for cancer.

  title={Promise and challenge of RNA interference-based therapy for cancer.},
  author={Fabio Petrocca and Judy Lieberman},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  volume={29 6},
  • F. PetroccaJ. Lieberman
  • Published 20 February 2011
  • Biology
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Cancer therapeutics still fall far short of our goals for treating patients with locally advanced or metastatic disease. Until recently, almost all cancer drugs were crude cytotoxic agents that discriminate poorly between cancer cells and normally dividing cells. The development of targeted biologics that recognize tumor cell surface antigens and of specific inhibitors of pathways dysregulated in cancer cells or normal cellular pathways on which a cancer cell differentially depends has provided… 

Figures and Tables from this paper

RNA Interference and Nanotechnology: A Promising Alliance for Next Generation Cancer Therapeutics

Different types of nano-based delivery strategies for engineering Nano-RNAi-based bio drugs are highlighted and the insights gained from current research that are entering the preclinical evaluation and information about initial clinical developments are highlighted, shaping the future for next generation cancer therapeutics.

Downregulation of PIK3CA via antibody-esiRNA-complexes suppresses human xenograft tumor growth

The use of antibody-esiRNA complexes as a novel experimental treatment option against key components of the EGFR signaling cascade is proposed and a significant decrease in tumor growth is identified upon this treatment due to decreased tumor cell proliferation.

From RNA interference technology to effective therapy: how far have we come and how far to go?

The emergence of a novel application of RNAi in enhancing the delivery of low-molecular weight drugs to neuronal tissues and the potential side effects associated with exploiting a crucial biological pathway for therapeutic benefit are presented.

Multifunctional aptamer-miRNA conjugates for targeted cancer therapy.

The development of aptamer-miRNA conjugates as multifunctional molecules that inhibit the growth of Axl-expressing tumors are described and established as a novel tool for targeted delivery of miRNAs with therapeutic potential.

A novel platform to enable inhaled naked RNAi medicine for lung cancer

A naked and unmodified novel RNAi agent, such as ribophorin II (RPN2-PnkRNA), which has been selected as a therapeutic target for lung cancer, resulted in efficient inhibition of tumor growth without any significant toxicity, suggesting this new technology using aerosol delivery could represent a safe, potentially RNAi-based strategy for clinical applications in lung cancer treatment without delivery vehicles.

Biodegradable nanocarriers for small interfering ribonucleic acid (siRNA) co-delivery strategy increase the chemosensitivity of pancreatic cancer cells to gemcitabine

Biodegradable charged polyester-based vectors were synthesized for the co-delivery of K-ras and Notch1 small interfering ribonucleic acid into MiaPaCa-2 cells to overcome drug resistance to gemcitabine, a first-line chemotherapeutic drug used in the clinic.

Non-Small Cell Lung Carcinoma: An Overview on Targeted Therapy.

This work revise the recent findings concerning the therapeutic effects of molecular variations associated with NSCLC and where targeted therapies stand in its treatment, with special focus on RNAi-mediated gene silencing as a powerful strategy forNSCLC treatment.



RNAi nanoparticles in the service of personalized medicine.

A substantial effort is invested in developing a new class of molecular diagnostic tools identifying patients’ tumor-personal gene-expression signatures, as well as mutation profiles that can be activated by incorporating small interferingRNAs into the cell.

MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy.

Findings are the first direct evidence that miRNAs can suppress resistance to anticancer cytotoxic therapy, a common feature of cancer cells, and suggest that miRNAAs may be a viable tool to augment current cancer therapies.

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

Evidence is provided of inducing an RNAi mechanism of action in a human from the delivered siRNA and the presence of an mRNA fragment that demonstrates that siRNA-mediated mRNA cleavage occurs specifically at the site predicted for anRNAi mechanism from a patient who received the highest dose of the nanoparticles.

Delivery vehicles for small interfering RNA in vivo.

Development of therapeutics using siRNA has advanced rapidly, with five different clinical trials ongoing and several more poised to enter the clinic in the coming years.

The let-7 microRNA reduces tumor growth in mouse models of lung cancer

Findings provide direct evidence that let-7 acts as a tumor suppressor gene in the lung and indicate that this miRNA may be useful as a novel therapeutic agent in lung cancer.

MicroRNA signatures in human ovarian cancer.

The results indicate that miRNAs might play a role in the pathogenesis of human EOC and identify altered miRNA gene methylation as a possible epigenetic mechanism involved in their aberrant expression.

RNAi-mediated gene silencing in non-human primates

It is shown that siRNAs, when delivered systemically in a liposomal formulation, can silence the disease target apolipoprotein B in non-human primates, supporting RNAi therapeutics as a potential new class of drugs.

Suppression of non-small cell lung tumor development by the let-7 microRNA family

It is shown that let-7 functionally inhibits non-small cell tumor development and was more potent in lung cancer cell lines harboring oncogenic K-Ras mutations than in lines with other mutations.

Endogenous human microRNAs that suppress breast cancer metastasis

It is shown that restoring the expression of these microRNAs in malignant cells suppresses lung and bone metastasis by human cancer cells in vivo, and miR-126 restoration reduces overall tumour growth and proliferation, whereasmiR-335 inhibits metastatic cell invasion.